Sanofi Starts Fund For The Concerned In Low-Income Nations

The Paris-based pharmaceutical company is setting up a fund to assist companies who want to provide healthcare solutions in neglected areas. The objective is to assist in the establishment of locally resilient organisations.

According to Jon Fairest of Sanofi, innovation from his expertise on the African continent and the digitization of new enterprises is very spectacular. However, they may not receive the financing and investment that they do in the more developed world because they may not have the visibility that they do.

Fairest, who oversaw Sanofi’s operations in Africa for six of his 20+ years there, now serves as the unit’s leader for global health. The non-profit organisation was founded in April of last year with the goal of distributing medications and supporting healthcare systems in underdeveloped nations. Sanofi offers 40 underdeveloped countries throughout the world 30 of its medications at no cost. The World Health Organization has classified all of the treatments as essential medications. They cover a wide range of therapeutic areas, but Sanofi lays particular focus on goods for diabetes, cancer, and tuberculosis.

In terms of the number of people with cardio/metabolic diseases in these nations, it’s often a pandemic in itself, according to Fairest. No one has received training on even how to manage it. They are truly leaving a legacy in terms of general healthcare when they enter a country and are successful with a programme.

Sanofi announced recently that it is introducing an Impact brand to further distinguish its not-for-profit products. According to Fairest, the initiative will aid in increasing the effectiveness and efficiency of the 30 different medications’ delivery.

The host countries must be committed to giving the Impact project a chance to succeed. Sanofi travels to choose which countries to start in, most recently to Rwanda. According to Fairest, it will be simpler to introduce Impact to adjacent nations once success has been established. The Sanofi project has so far reached about 150,000 patients. The only way the business can achieve its future goal of making millions is by creating processes that are scalable and self-sustaining.

They won’t continue to invest indefinitely. Fairest added that they would anticipate them carrying this forward once they construct the model and feel that people are benefiting. They desire knowledge. Starting with a few target nations, they will consider the next steps before moving on.